| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Apr, 2025 | Apr, 2025 | Apr, 2025 |
| Sales | 13,960 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -40,620 | -4,720 | 0 | 0 | 0 |
| Net Income Growth | -760.59% | unch | unch | unch | unch |
Clarus Therapeutics Hldgs Inc (CRXT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0475 -0.0215 (-31.16%) 09/06/22 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.0475 unch (unch) -
for Tue, Sep 6th, 2022
Clarus Therapeutics Inc. is a specialty pharmaceutical company which provide solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women. The Company's commercial product includes JATENZO(R). Clarus Therapeutics Inc., formerly known as Blue Water Acquisition Corp., is based in NORTHBROOK, Ill.